Pluvicto (lutetium Lu 177 vipivotide tetraxetan) - Novartis
Association of ATM Alterations with Outcomes After 177Lu-PSMA-617 Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer. (PubMed, J Nucl Med) - Sep 25, 2026 - " ATM alterations were independently associated with improved outcomes after treatment with 177Lu-PSMA-617 and validated across a pooled analysis. Marked heterogeneity among individual HRR genes was observed, supporting gene-level rather than composite HRR analysis for precision oncology in radiopharmaceutical therapy." 
Journal • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • ATM • BRCA2 • CDK12 • HRD • SPOP • TP53
http://www.ncbi.nlm.nih.gov/pubmed/42785951
 
Ali T Arafa; Ella Boytim; Emmanuel S Antonarakis; Ian J Okazaki; Justin Hwang; Lauren Yu; Lily Kollitz; Nicholas A Zorko; Scott M Dehm; Vikrant Mahajan; Zuzan Cayci
 
Sep 25, 2026
 
Prev Next